Moderna 

$43.35
2666
-$0.72-1.63% Today

Statistics

Day High
43.75
Day Low
41.63
52W High
55.2
52W Low
22.28
Volume
5,007,536
Avg. Volume
11,803,831
Mkt Cap
16.94B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-3.35
-2.22
-1.1
0.03
Expected EPS
-2.544462
Actual EPS
N/A

Financials

-110.04%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
6.47BRevenue
-7.12BNet Income

Analyst Ratings

$29.70Average Price Target
The highest estimate is 63.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
9%
Hold
64%
Sell
27%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MRNA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a direct competitor in the COVID-19 vaccine market, with its mRNA vaccine developed in collaboration with BioNTech.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE partnered with Pfizer to develop a COVID-19 mRNA vaccine, competing directly with Moderna's mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson competes in the COVID-19 vaccine space with its viral vector vaccine, offering an alternative to mRNA vaccines.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Moderna with its COVID-19 vaccine developed in collaboration with Oxford University, using a different technology (viral vector).
Novavax
NVAX
Mkt Cap1.36B
Novavax offers a protein subunit COVID-19 vaccine, providing an alternative to Moderna's mRNA vaccine.
Sanofi
SNY
Mkt Cap124.45B
Sanofi, through its partnership with GlaxoSmithKline, is developing COVID-19 vaccines that compete with Moderna's offerings.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, in collaboration with Sanofi, is working on COVID-19 vaccines, positioning it as a competitor to Moderna.
CureVac N.V.
CVAC
Mkt Cap1.2B
CureVac competes in the mRNA space, focusing on developing mRNA-based vaccines and therapeutics, including for COVID-19.
Merck
MRK
Mkt Cap214.76B
Merck is involved in the development of COVID-19 treatments and vaccines, making it a competitor in the broader infectious disease market.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories competes with Moderna in the broader healthcare sector, including diagnostics and medical devices for infectious diseases.

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Stéphane Bancel
Employees
5800
Country
US
ISIN
US60770K1079

Listings

0 Comments

Share your thoughts

FAQ

What is Moderna stock price today?
The current price of MRNA is $43.35 USD — it has decreased by -1.63% in the past 24 hours. Watch Moderna stock price performance more closely on the chart.
What is Moderna stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Moderna stocks are traded under the ticker MRNA.
Is Moderna stock price growing?
MRNA stock has fallen by -9.63% compared to the previous week, the month change is a +40.54% rise, over the last year Moderna has showed a +10.02% increase.
What is Moderna market cap?
Today Moderna has the market capitalization of 16.94B
When is the next Moderna earnings date?
Moderna is going to release the next earnings report on February 13, 2026.
What were Moderna earnings last quarter?
MRNA earnings for the last quarter are -0.51 USD per share, whereas the estimation was -1.87 USD resulting in a +72.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Moderna revenue for the last year?
Moderna revenue for the last year amounts to 6.47B USD.
What is Moderna net income for the last year?
MRNA net income for the last year is -7.12B USD.
How many employees does Moderna have?
As of February 02, 2026, the company has 5,800 employees.
In which sector is Moderna located?
Moderna operates in the Health Care sector.
When did Moderna complete a stock split?
The last stock split for Moderna was on August 03, 2017 with a ratio of 1:10.
Where is Moderna headquartered?
Moderna is headquartered in Cambridge, US.